Published in J Immunother on June 20, 2002
Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev (2014) 1.81
Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. J Gene Med (2012) 1.40
Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opin Biol Ther (2011) 1.27
Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. Proc Natl Acad Sci U S A (2005) 1.14
Engineering T cells for cancer therapy. Br J Cancer (2005) 1.05
Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy. Br J Cancer (2005) 1.04
Engineering T cell function using chimeric antigen receptors identified using a DNA library approach. PLoS One (2013) 0.84
Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells. ISRN Oncol (2012) 0.84
Efficient and reproducible generation of tumour-infiltrating lymphocytes for renal cell carcinoma. Br J Cancer (2015) 0.83
T lymphocytes isolated from patients with advanced colorectal cancer are suitable for gene immunotherapy approaches. Br J Cancer (2003) 0.80
Engineered T cells for cancer treatment. Cytotherapy (2013) 0.78
CD3ζ-based chimeric antigen receptors mediate T cell activation via cis- and trans-signalling mechanisms: implications for optimization of receptor structure for adoptive cell therapy. Clin Exp Immunol (2014) 0.78
The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity. Cancer Immunol Immunother (2017) 0.75
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol (2010) 13.03
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer (2013) 2.51
Prevention of amino acid conversion in SILAC experiments with embryonic stem cells. Mol Cell Proteomics (2008) 1.83
Early and late onset Clostridium difficile-associated colitis following liver transplantation. Transpl Int (2007) 1.62
The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. J Immunother (2005) 1.50
Educational impact of an assessment of medical students' collaboration in health care teams. Med Educ (2014) 1.42
Retroviral transduction with SOX9 enhances re-expression of the chondrocyte phenotype in passaged osteoarthritic human articular chondrocytes. Osteoarthritis Cartilage (2005) 1.34
Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol Immunother (2007) 1.32
CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe. Trends Mol Med (2012) 1.32
Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res (2010) 1.30
Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells. J Immunol (2010) 1.25
Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. Clin Cancer Res (2006) 1.24
Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. Clin Cancer Res (2010) 1.14
Building better chimeric antigen receptors for adoptive T cell therapy. Curr Gene Ther (2010) 1.10
An enhanced mass spectrometry approach reveals human embryonic stem cell growth factors in culture. Mol Cell Proteomics (2008) 1.09
Cancer vaccines and immunotherapy. Br Med Bull (2002) 1.07
Transduction of passaged human articular chondrocytes with adenoviral, retroviral, and lentiviral vectors and the effects of enhanced expression of SOX9. Tissue Eng (2004) 1.04
Do CARs need a driver's license? Adoptive cell therapy with chimeric antigen receptor-redirected T cells has caused serious adverse events. Hum Gene Ther (2010) 1.04
T cell-based immunotherapy of metastatic renal cell carcinoma: modest success and future perspective. Clin Cancer Res (2009) 1.04
Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. Cancer Immunol Immunother (2008) 1.03
CAR T cells: driving the road from the laboratory to the clinic. Immunol Rev (2014) 1.03
The combination of cyclophosphamide and human T cells genetically engineered to target CD19 can eradicate established B-cell lymphoma. Br J Haematol (2008) 1.02
T regulatory cells in cancer: recent advances and therapeutic potential. Expert Opin Biol Ther (2010) 1.02
Killing of non-Hodgkin lymphoma cells by autologous CD19 engineered T cells. Br J Haematol (2005) 1.00
The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex. J Immunol (2010) 0.99
Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells. Clin Immunol (2010) 0.99
Ion mobility mass spectrometry analysis of human glycourinome. Anal Chem (2008) 0.98
Targeted immunotherapy of cancer with CAR T cells: achievements and challenges. Cancer Immunol Immunother (2012) 0.98
Ion mobility separation coupled with MS detects two structural states of Alzheimer's disease Aβ1-40 peptide oligomers. J Mol Biol (2011) 0.96
Expanded subpopulation of FoxP3+ T regulatory cells in renal cell carcinoma co-express Helios, indicating they could be derived from natural but not induced Tregs. Clin Immunol (2011) 0.95
Using ion purity scores for enhancing quantitative accuracy and precision in complex proteomics samples. Anal Bioanal Chem (2012) 0.93
Vaccine and antibody-directed T cell tumour immunotherapy. Biochim Biophys Acta (2004) 0.93
Eotaxin-2 and colorectal cancer: a potential target for immune therapy. Clin Cancer Res (2007) 0.93
Functional expression of secreted proteins from a bicistronic retroviral cassette based on foot-and-mouth disease virus 2A can be position dependent. Hum Gene Ther (2010) 0.93
Eradication of established B-cell lymphoma by CD19-specific murine T cells is dependent on host lymphopenic environment and can be mediated by CD4+ and CD8+ T cells. J Immunother (2009) 0.90
Combination of vaccination and chimeric receptor expressing T cells provides improved active therapy of tumors. J Immunol (2006) 0.90
Using ion mobility data to improve peptide identification: intrinsic amino acid size parameters. J Proteome Res (2011) 0.89
An MVA-based vaccine targeting the oncofetal antigen 5T4 in patients undergoing surgical resection of colorectal cancer liver metastases. J Immunother (2008) 0.89
Engineering T-cells with antibody-based chimeric receptors for effective cancer therapy. Curr Opin Mol Ther (2005) 0.87
Use of adenoviruses encoding CD40L or IL-2 against B cell lymphoma. Int J Cancer (2004) 0.87
CSF biomarker discovery using label-free nano-LC-MS based proteomic profiling: technical aspects. J Sep Sci (2007) 0.87
Real-time Seldinger technique simulation in complex vascular models. Int J Comput Assist Radiol Surg (2009) 0.86
High-dose interleukin-2 can produce a high rate of response and durable remissions in appropriately selected patients with metastatic renal cancer. J Immunother (2011) 0.86
Immunotherapy for gastrointestinal cancer: current status and strategies for improving efficacy. Expert Opin Biol Ther (2008) 0.86
Adoptive transfer of T(reg) depleted autologous T cells in advanced renal cell carcinoma. Cancer Immunol Immunother (2007) 0.85
Development of a flow cytometric co-immunoprecipitation technique for the study of multiple protein-protein interactions and its application to T-cell receptor analysis. Cytometry A (2010) 0.85
Overcoming the toxicity hurdles of genetically targeted T cells. Cancer Immunol Immunother (2014) 0.85
A probabilistic framework for peptide and protein quantification from data-dependent and data-independent LC-MS proteomics experiments. OMICS (2012) 0.85
Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4). Cancer Immunol Immunother (2009) 0.85
Potential limitations of the NSG humanized mouse as a model system to optimize engineered human T cell therapy for cancer. Hum Gene Ther Methods (2013) 0.84
Cytokine stimulation and the choice of promoter are critical factors for the efficient transduction of mouse T cells with HIV-1 vectors. J Gene Med (2010) 0.84
A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma. Cancer Chemother Pharmacol (2007) 0.84
Gene therapy of patient-derived T lymphocytes to target and eradicate colorectal hepatic metastases. Dis Colon Rectum (2003) 0.84
Gene delivery of a mutant TGFβ3 reduces markers of scar tissue formation after cutaneous wounding. Mol Ther (2010) 0.84
Nonionic detergent phase extraction for the proteomic analysis of heart membrane proteins using label-free LC-MS. Proteomics (2008) 0.83
CD8 T-cell recognition of human 5T4 oncofetal antigen. Int J Cancer (2006) 0.83
GADD45a-GFP GreenScreen HC assay results for the ECVAM recommended lists of genotoxic and non-genotoxic chemicals for assessment of new genotoxicity tests. Mutat Res (2009) 0.83
Identification of a major histocompatibility complex class I-restricted T-cell epitope in the tumour-associated antigen, 5T4. Immunology (2006) 0.83
Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope. J Immunol (2002) 0.83
Differential role of Th1 and Th2 cytokines in autotoxicity driven by CD19-specific second-generation chimeric antigen receptor T cells in a mouse model. J Immunol (2014) 0.82
Development of a novel recombinant biotherapeutic with applications in targeted therapy of human arthritis. Arthritis Rheum (2011) 0.82
A phase II study of weekly cisplatin and gemcitabine in patients with advanced pancreatic cancer: is this a strategy still worth pursuing? Pancreas (2006) 0.82
Simulating and validating proteomics data and search results. Proteomics (2011) 0.81
Comparison of one- and two-dimensional liquid chromatography approaches in the label-free quantitative analysis of Methylocella silvestris. J Proteome Res (2012) 0.81
Amplification of epidermal growth factor receptor gene in renal cell carcinoma. Eur J Cancer (2010) 0.81
Assessment of the genotoxicity of S9-generated metabolites using the GreenScreen HC GADD45a-GFP assay. Mutagenesis (2008) 0.81
Targeting of viral interleukin-10 with an antibody fragment specific to damaged arthritic cartilage improves its therapeutic potency. Arthritis Res Ther (2014) 0.81
MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients. Cancer Immunol Immunother (2011) 0.81
Anti-angiogenic therapy in the treatment of advanced renal cell cancer. Cancer Treat Rev (2006) 0.81
The Teamwork Mini-Clinical Evaluation Exercise (T-MEX): a workplace-based assessment focusing on collaborative competencies in health care. Acad Med (2014) 0.80
Definition and application of good manufacturing process-compliant production of CEA-specific chimeric antigen receptor expressing T-cells for phase I/II clinical trial. Cancer Immunol Immunother (2013) 0.80
5T4 as a target for immunotherapy in renal cell carcinoma. Expert Rev Anticancer Ther (2009) 0.80
An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma. Oncology (2014) 0.80
What do students want? The types of learning activities preferred by final year medical students. Med Educ (2003) 0.79
CD4+ T-cell recognition of human 5T4 oncofoetal antigen: implications for initial depletion of CD25+ T cells. Cancer Immunol Immunother (2007) 0.79
Aboriginal and Torres Strait Islander women's health: acting now for a healthy future. Aust N Z J Obstet Gynaecol (2008) 0.78
Asymmetric proteome equalization of the skeletal muscle proteome using a combinatorial hexapeptide library. PLoS One (2011) 0.77
Additional precursor purification in isobaric mass tagging experiments by traveling wave ion mobility separation (TWIMS). J Proteome Res (2014) 0.77
In vitro effect of IL-2 in combination with pazopanib or sunitinib on lymphocytes function and apoptosis of RCC cells. Expert Opin Pharmacother (2014) 0.77
Adoptive transfer of anti-idiotypic T cells cure mice of disseminated B cell lymphoma. J Immunother (2004) 0.77
Relationship between active cervical range of motion and perceived neck disability in community dwelling elderly individuals. J Geriatr Phys Ther (2005) 0.77
Isolation of tumor antigen-specific single-chain variable fragments using a chimeric antigen receptor bicistronic retroviral vector in a Mammalian screening protocol. Hum Gene Ther Methods (2013) 0.76
Antibody-directed enzyme-prodrug therapy. Methods Mol Med (2004) 0.76
Yeast prion [PSI+] lowers the levels of mitochondrial prohibitins. Biochim Biophys Acta (2009) 0.76
Qualitative and quantitative multiplexed proteomic analysis of complex yeast protein fractions that modulate the assembly of the yeast prion Sup35p. PLoS One (2011) 0.76
Counting swabs. Br J Perioper Nurs (2005) 0.75
An 'insulting' letter. Nurs N Z (2009) 0.75
The Use of an Indwelling Catheter Protocol to Reduce Rates of Postoperative Urinary Tract Infections. Conn Med (2016) 0.75
Cellular therapy of cancer symposium December 2nd-3rd 2006 Manchester, UK. Cancer Immunol Immunother (2007) 0.75
Engineering stem cells for therapy. Regen Med (2006) 0.75
Toward personalized immunotherapy for non-Hodgkin lymphoma: targeting the idiotypic immunoglobulin. BioDrugs (2005) 0.75
Patients with pancreatic cancer participating in clinical trials: are targets being met, and if not, why? Pancreas (2007) 0.75
The second cellular therapy of cancer symposium, 27-29 March 2009, Milan, Italy. Cancer Immunol Immunother (2009) 0.75